Cargando…

Effectiveness of L-asparaginase-based regimens compared to anthracycline-based regimens in newly diagnosed extranodal NK/T-cell lymphoma, nasal type: a single Mexican center experience

BACKGROUND: Extranodal NK/T-cell lymphoma, nasal type (ENKTCL) has a high prevalence in Asia and Latin American countries, such as Mexico, where it encompasses 40% of all T-cell non-Hodgkin lymphomas. Historically, responses to anthracycline-based therapies have been disappointing. Since data about...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ávila Milord, AL A., Aguilar Hernández, María M., Demichelis Gómez, Roberta, Agreda Vásquez, Gladys P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170315/ https://www.ncbi.nlm.nih.gov/pubmed/30310787 http://dx.doi.org/10.5045/br.2018.53.3.210

Ejemplares similares

Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma
por: Wu, Wanchun, et al.
Publicado: (2023)

A controlling nutritional status score is an independent predictor for patients with newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma based on asparaginase‐containing regimens
por: Wu, Wanchun, et al.
Publicado: (2023)

“Sandwich” protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study
por: Shen, Cheng-qi, et al.
Publicado: (2023)

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type
por: Lin, Ningjing, et al.
Publicado: (2013)

Evaluation of different staging systems and prognostic analysis of nasal-type extranodal NK/T-cell lymphoma based on consistent LVDP chemotherapy regimen
por: Wu, Wanchun, et al.
Publicado: (2022)

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
por: Zhang, Lei, et al.
Publicado: (2016)

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T‐cell lymphoma patients
por: Liu, Yizhen, et al.
Publicado: (2020)

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Kim, Hyun Jee, et al.
Publicado: (2018)

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008)
por: Yoon, Dok Hyun, et al.
Publicado: (2016)

Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination
por: Wang, Yu, et al.
Publicado: (2022)

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
por: Tan, Qiu-Wen, et al.
Publicado: (2017)

LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma
por: Wang, Liang, et al.
Publicado: (2021)

Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis
por: Wei, Liqiang, et al.
Publicado: (2020)

Multifocal primary cutaneous extranodal NK/T lymphoma nasal type
por: de Vasconcelos, Pedro, et al.
Publicado: (2016)

Educational Case: Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Jia, Yue, et al.
Publicado: (2019)

Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK/T cell lymphoma: A prospective single-center phase II study
por: Zhu, Fang, et al.
Publicado: (2020)

Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens
por: Yersal, Özlem, et al.
Publicado: (2018)

Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase
por: Gao, Tianxiao, et al.
Publicado: (2023)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Shi, Zhuangzhuang, et al.
Publicado: (2021)

Extranodal nasal-type NK/T-cell lymphoma of the palate and paranasal sinuses
por: Nikolaos, Nikitakis, et al.
Publicado: (2012)

Nasal-type extranodal T-cell/NK lymphoma in association with hemophagocytic syndrome
por: Guedes, Juliana Chaves Ruiz, et al.
Publicado: (2018)

Extranodal NK/T-cell lymphoma, nasal type with extensive cardiopulmonary involvement
por: Marques-Piubelli, Mario L., et al.
Publicado: (2021)

Clinical and otorhinolaryngological aspects of extranodal NK/T cell lymphoma, nasal type()()
por: Miyake, Marcel Menon, et al.
Publicado: (2014)

A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy
por: Cao, Jianzhong, et al.
Publicado: (2016)

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval
por: Iqbal, Mohammad, et al.
Publicado: (2020)

Feasibility of low-dose radiotherapy for patients with stage I/II extranodal NK-/T-cell lymphoma, nasal type achieving complete response after l-asparaginase-containing chemotherapy
por: Kim, Jae Sik, et al.
Publicado: (2022)

Extranodal NK/T cell lymphoma, nasal type: a rare diagnosis with common nasal presentation
por: Mohd Ramli, Siti Sarah, et al.
Publicado: (2021)

Extranodal NK-T-Cell Lymphoma, Nasal-Type Misdiagnosed as Erythema Multiforme with Nasal Fungal Infection
por: Jeong, Soo Hyun, et al.
Publicado: (2022)

Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study
por: Zheng, X., et al.
Publicado: (2021)

Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
por: Wang, Zhipeng, et al.
Publicado: (2018)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

Extranodal NK/T-Cell Lymphoma, Nasal Type, Presenting as a Breast Mass
por: Rahal, Ahmad, et al.
Publicado: (2015)

Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type
por: Lo Bello, Giuseppe, et al.
Publicado: (2018)

Extranodal NK/T-cell lymphoma, nasal type without evidence of EBV infection
por: Wang, Wei, et al.
Publicado: (2020)

Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma
por: Ke, Q-H, et al.
Publicado: (2014)

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen
por: Chen, Ruiqi, et al.
Publicado: (2020)

Extranodal NK/T cell lymphoma
por: Jeong, Seong Hyun
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bmsigf75ivnklcuoiaqam4rvfa